Literature DB >> 10221263

Characterization of the enzymatic activity of PSM: comparison with brain NAALADase.

C W Tiffany1, R G Lapidus, A Merion, D C Calvin, B S Slusher.   

Abstract

BACKGROUND: The prostate cancer marker prostate-specific membrane antigen (PSM) is highly homologous to the brain enzyme N-acetylated alpha-linked acidic dipeptidase (NAALADase). NAALADase is known to cleave terminal carboxy glutamates from both the neuronal peptide N-acetylaspartylglutamate (NAAG) and folate polyglutamate. In this report, we compare the NAAG hydrolyzing activity of NAALADase and the prostate enzyme PSM.
METHODS: Using a NAAG hydrolytic radioenzymatic assay, we compared the pharmacological and kinetic properties of the brain and prostate enzymes.
RESULTS: Eight normal prostate tissues from different species exhibited NAAG hydrolyzing activity. Among 14 cancer cell lines examined, activity was observed in human LNCaP, PC-82, and rat Dunning G and AT-1 cells. Brain exhibited membrane-localized activity exclusively, while the prostate enzyme had activity in both membrane and cytosolic fractions. The only observed pharmacological difference was the sensitivity to their putative substrates, folate polyglutamate and NAAG. Kinetically, the soluble form of the prostate enzyme had two catalytic sites, while the membrane-bound form exhibited single site kinetics with a lower Vmax than the brain enzyme, which may suggest a less active hydrolase in the prostate.
CONCLUSIONS: The brain enzyme NAALADase and the prostate enzyme PSM are remarkably similar. The importance of the differences in substrate specificities and kinetic parameters remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10221263     DOI: 10.1002/(sici)1097-0045(19990401)39:1<28::aid-pros5>3.0.co;2-a

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  22 in total

Review 1.  Anatomic and Molecular Imaging in Prostate Cancer.

Authors:  Eric T Miller; Amirali Salmasi; Robert E Reiter
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

2.  Design and synthesis of a siderophore conjugate as a potent PSMA inhibitor and potential diagnostic agent for prostate cancer.

Authors:  Pingyu Ding; Paul Helquist; Marvin J Miller
Journal:  Bioorg Med Chem       Date:  2007-11-17       Impact factor: 3.641

Review 3.  Current use of PSMA-PET in prostate cancer management.

Authors:  Tobias Maurer; Matthias Eiber; Markus Schwaiger; Jürgen E Gschwend
Journal:  Nat Rev Urol       Date:  2016-02-23       Impact factor: 14.432

4.  Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction.

Authors:  Rebecca E Conway; Nenad Petrovic; Zhong Li; Warren Heston; Dianqing Wu; Linda H Shapiro
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

5.  18F-Positron Emitting/Trimethine Cyanine-Fluorescent Contrast for Image-Guided Prostate Cancer Management.

Authors:  Harikrishna Kommidi; Hua Guo; Fuad Nurili; Yogindra Vedvyas; Moonsoo M Jin; Timothy D McClure; Behfar Ehdaie; Haluk B Sayman; Oguz Akin; Omer Aras; Richard Ting
Journal:  J Med Chem       Date:  2018-04-20       Impact factor: 7.446

6.  The Arabidopsis AMP1 gene encodes a putative glutamate carboxypeptidase.

Authors:  C A Helliwell; A N Chin-Atkins; I W Wilson; R Chapple; E S Dennis; A Chaudhury
Journal:  Plant Cell       Date:  2001-09       Impact factor: 11.277

7.  Substrate specificity of prostate-specific membrane antigen.

Authors:  Marc O Anderson; Lisa Y Wu; Nicholas M Santiago; Jamie M Moser; Jennifer A Rowley; Erin S D Bolstad; Clifford E Berkman
Journal:  Bioorg Med Chem       Date:  2007-08-11       Impact factor: 3.641

8.  Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.

Authors:  Shawn M Hillier; Kevin P Maresca; Frank J Femia; John C Marquis; Catherine A Foss; Nghi Nguyen; Craig N Zimmerman; John A Barrett; William C Eckelman; Martin G Pomper; John L Joyal; John W Babich
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

9.  Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen.

Authors:  Lisa Y Wu; Jacinda C Do; Marat Kazak; Helen Page; Yoko Toriyabe; Marc O Anderson; Clifford E Berkman
Journal:  Bioorg Med Chem Lett       Date:  2007-10-30       Impact factor: 2.823

10.  Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.

Authors:  Vikas Prasad; Ingo G Steffen; Gerd Diederichs; Marcus R Makowski; Peter Wust; Winfried Brenner
Journal:  Mol Imaging Biol       Date:  2016-06       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.